Previous studies have shown that AML patients can express low levels or high levels of CD13 on the surface of their leukemic cells and patients that express low CD13 transcript levels and have low CD13 surface protein expression tend to survive longer than patients with higher CD13 levels [26]. This evidence concerns the gene ANPEP and acute myeloid leukemia.